Richard Doubleday Net Worth

The estimated Net Worth of Richard Doubleday is at least $35.1 Milión dollars as of 23 March 2021. Mr. Doubleday owns over 1,109 units of Dexcom Inc stock worth over $455,599 and over the last 15 years he sold DXCM stock worth over $31,359,493. In addition, he makes $3,274,180 as Executive Vice President a Chief Commercial Officer at Dexcom Inc.

Mr. Doubleday DXCM stock SEC Form 4 insiders trading

Richard has made over 95 trades of the Dexcom Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 1,109 units of DXCM stock worth $399,783 on 23 March 2021.

The largest trade he's ever made was exercising 50,000 units of Dexcom Inc stock on 11 March 2014 worth over $301,500. On average, Richard trades about 3,049 units every 24 days since 2009. As of 23 March 2021 he still owns at least 6,654 units of Dexcom Inc stock.

You can see the complete history of Mr. Doubleday stock trades at the bottom of the page.

Richard Doubleday biography

Richard B. Doubleday is no longer serves as Executive Vice President, Chief Commercial Officer of the Company effective 12/31/2020. He has served as our Executive Vice President, Chief Commercial Officer since January 2015. From February 2013 to January 2015, Mr. Doubleday served as our Senior Vice President of Worldwide Sales and Marketing. From June 2009 to February 2013, Mr. Doubleday served as our Vice President of Sales. From May 1988 to June 2009, Mr. Doubleday served in various roles for Johnson & Johnson, Inc. (“J&J”), including Director of Marketing for J&J subsidiary Animas Corporation, a manufacturer of insulin pumps, from July 2006 to June 2009, and Field Sales Director for J&J subsidiary LifeScan, Inc., a manufacturer of blood glucose monitoring systems, from August 2002 to October 2005. Mr. Doubleday received a B.A. from Michigan State University.

What is the salary of Richard Doubleday?

As the Executive Vice President a Chief Commercial Officer of Dexcom Inc, the total compensation of Richard Doubleday at Dexcom Inc is $3,274,180. There are 2 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.

How old is Richard Doubleday?

Richard Doubleday is 57, he's been the Executive Vice President a Chief Commercial Officer of Dexcom Inc since 2015. There are 15 older and 14 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..

What's Richard Doubleday's mailing address?

Richard's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Dexcom Inc

Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff a Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Mr. Doubleday stock trades at Dexcom Inc

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

• Kevin Sayer,
  Chairman of the Board, President, Chief Executive Officer
• Quentin Blackford,
  Chief Financial Officer, Chief Operating Officer
• Richard Doubleday,
  Executive Vice President, Chief Commercial Officer
• Andrew Balo,
  Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
• Steven Pacelli,
  Executive Vice President - Strategy and Corporate Development
• Donald Abbey,
  Executive Vice President - Quality and Regulatory Affairs
• Kevin Ronald Sayer,
  Exec. Chairman, CEO & Pres
• Jacob Steven Leach,
  Exec. VP & CTO
• Bridgette Heller,
  Independent Director
• Mark Foletta,
  Lead Independent Director
• Eric Topol,
  Independent Director
• Jay Skyler,
  Independent Director
• Nicholas Augustinos,
  Independent Director
• Steven Altman,
  Independent Director
• Barbara Kahn,
  Independent Director
• Richard Collins,
  Independent Director
• Kyle Malady,
  Independent Director
• Karen Dahut,
  Independent Director
• Shelly Selvaraj,
  Senior Vice President - Information Technology
• Jeffrey Moy,
  Senior Vice President - Operations
• Jereme Sylvain,
  Senior Vice President - Finance, Chief Accounting Officer
• Patrick Murphy,
  Executive Vice President, Chief Legal Officer
• Jake Leach,
  Executive Vice President, Chief Technology Officer
• Shelly Ramasamy Selvaraj,
  Sr. VP of Information Technology
• Donald M. Abbey,
  Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
• Steven R. Pacelli,
  Exec. VP & MD of Dexcom Ventures
• Andrew K. Balo,
  Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
• Sadie M. Stern,
  Exec. VP & Chief HR Officer
• Chad M. Patterson,
  Exec. VP of Global Marketing
• Sean Christensen,
  Director of Corp. Affairs & Head of Investor Relations
• Jereme M. Sylvain,
  Exec. VP, CFO & Chief Accounting Officer
• John Lister,
  VP, Legal Affairs
• Terrance H Gregg,
  Director
• Jess Roper,
  VP, CFO
• Jorge A Valdes,
  Vice President of Engineering
• Girish Naganathan,
  EVP Chief Technology Officer
• Heather S Ace,
  SVP Human Resources
• Kevin M Sun,
  VP, Corp Controller & Treasury
• Jonathan T Md Lord,
  Director
• Glen D Nelson,
  Director
• Peter Gerhardsson,
  VP, Int'l Business Development
• David Carner,
  VP, Quality Assurance
• Laura Johnson,
  V.P., Intellectual Property
• Martin Doordan,
  Director
• Sean Carney,
  Director
• John Riolo,
  VP of Quality Assurance
• Claudia Graham,
  VP, Marketing
• Donald A Lucas,
  Director
• Donald L Lucas,
  Director
• Mark Brister,
  VP, Advanced Development Teams
• Richard Yang,
  V.P., Strategic Affairs
• James H Brauker,
  VP, Research & Development
• Rodney L Kellogg,
  Vice President of Sales
• Andrew P Rasdal,
  President and CEO
• Steven J Kemper,
  Chief Financial Officer
• Kim D Blickenstaff,
  Director
• Tae Andrews,
  Vice President of Marketing
• Paul Travelers Companies In...,
  
• Pincus Private Equity Viii ...,
  
• Brenton Karl Ahrens,
  Director
• Nancy Sfog City Management ...,
  
• Equity Partners Ii Llccanaa...,
  
• Paul Travelers Companies In...,
  
• Eric A Charmers Landing Llc...,
  
• Scott Lwindamere Llcwindame...,
  
• Equity Partners Ii Llc Waub...,
  
• Teri L Lawver,
  EVP Chief Commercial Officer
• Paul R Flynn,
  EVP Global Revenue
• Matthew Vincent Dolan,
  EVP Strategy and Corporate Dev
• Sumi Shrishrimal,
  SVP Chief Risk Officer
• Chad Patterson,
  EVP Global Marketing
• Barry J. Regan,
  EVP Operations
• Jacob Steven Leach,
  EVP, Chief Operating Officer
• Rimma Driscoll,
  Director
• Michael Jon Brown,
  EVP, Chief Legal Officer
• Sadie Stern,
  EVP, Chief HR Officer